SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion announced it is applying its AI-Immunology platform to…

Evaxion A/S · 6-K filed Sep 14, 2026 at 08:05 ET

At the news

NEUTRALIMPACT 3/10

6-K filed Sep 14, 2026 at 08:05 ET

Evaxion announced it is applying its AI-Immunology platform to autoimmune diseases, testing two novel treatment concepts (tolerogenic vaccine and autoantibody binder). Initial experimental data is expected at PEGS Europe in November 2026. This is a preclinical pipeline expansion with no financial data or near-term catalyst, representing a modest strategic update for a clinical-stage company.

  • Evaxion is applying its AI-Immunology platform to autoimmune diseases, expanding beyond cancer and infectious diseases.
  • Two novel concepts are being tested: a tolerogenic vaccine and an autoantibody binder.
  • Initial experimental data will be presented at PEGS Europe in Lisbon on November 18, 2026.
  • No financial terms, partnership agreements, or clinical trial data were disclosed in the filing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access